Dossier assessment
Baloxavir marboxil (influenza - post-exposure prophylaxis) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Baloxavir marboxil (influenza - post-exposure prophylaxis) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Baloxavir marboxil (influenza - post-exposure prophylaxis) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult and adolescent patients aged 12 years and above with influenza exposure
Affected people without risk of influenza-related complications: indication of considerable added benefit.
Affected people with risk of influenza-related complications: added benefit not proven.
Project details
- Project no.
- A21-22
- Commission
- Commission awarded on 12.02.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Baloxavir marboxil (influenza) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed